Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy
Hewei Ge, Yuhan Wei, Yalong Qi, Hongnan Mo, Jingtong Zhai, Cheng Zeng, Xiaoying Sun, Fei Ma · 2026
Read Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy by Hewei Ge, Yuhan Wei, Yalong Qi, Hongnan Mo, Jingtong Zhai, Cheng Zeng, Xiaoying Sun, Fei Ma (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13639012.txt.
Description
Hewei Ge and seven colleagues report a 2026 multi-center study on how a breast cancer feature called HER2-low affects immunotherapy results. Their focus was triple-negative breast cancer, an aggressive type with few treatment options.
Patients whose tumors had low HER2 levels responded worse to immunotherapy given before surgery than patients with no HER2, while chemotherapy alone showed no such gap. Two outside trial groups confirmed the pattern. Single-cell analysis showed the HER2-low tumors were less visible to the immune system and had quieter T cells. The authors say HER2-low status could help predict who benefits from immunotherapy.
Catalog record
| CREATOR | Hewei Ge, Yuhan Wei, Yalong Qi, Hongnan Mo, Jingtong Zhai, Cheng Zeng, Xiaoying Sun, Fei Ma |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 77017 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |